State of New Jersey Common Pension Fund D Cuts Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

State of New Jersey Common Pension Fund D lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 42.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 113,607 shares of the biotechnology company’s stock after selling 84,249 shares during the period. State of New Jersey Common Pension Fund D’s holdings in ADMA Biologics were worth $2,271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in shares of ADMA Biologics during the 2nd quarter worth $29,000. Hollencrest Capital Management acquired a new position in ADMA Biologics during the third quarter worth about $30,000. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at about $31,000. CWM LLC grew its position in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $93,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ADMA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright increased their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

Insider Activity at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The trade was a 5.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The trade was a 5.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by company insiders.

ADMA Biologics Price Performance

ADMA stock opened at $20.20 on Friday. The stock has a market capitalization of $4.71 billion, a price-to-earnings ratio of 72.14 and a beta of 0.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The stock’s fifty day simple moving average is $18.42 and its 200-day simple moving average is $14.22.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period last year, the company earned $0.01 EPS. Equities research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.